Cargando…

Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data

BACKGROUND: There are no published human studies investigating whether the use of allopurinol, the most commonly used medication for the treatment of hyperuricemia in gout, the most common type of inflammatory arthritis in adults, has any beneficial effects on ventricular electrophysiology. The obje...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Jasvinder A., Cleveland, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361697/
https://www.ncbi.nlm.nih.gov/pubmed/28327188
http://dx.doi.org/10.1186/s12916-017-0816-6
_version_ 1782516816496558080
author Singh, Jasvinder A.
Cleveland, John
author_facet Singh, Jasvinder A.
Cleveland, John
author_sort Singh, Jasvinder A.
collection PubMed
description BACKGROUND: There are no published human studies investigating whether the use of allopurinol, the most commonly used medication for the treatment of hyperuricemia in gout, the most common type of inflammatory arthritis in adults, has any beneficial effects on ventricular electrophysiology. The objective of our study was to assess whether allopurinol use is associated with a reduction in the risk of ventricular arrhythmias (VA). METHODS: We used the 5% random sample of Medicare beneficiaries from 2006–2012 to examine new allopurinol use and the risk of incident VA. Multivariable Cox regression analyses were adjusted for demographics (age, race, sex), comorbidity, cardiac medications, and conditions associated with VA. We calculated hazard ratios (HR) and 95% confidence intervals (CI). RESULTS: Of the 28,755 episodes of new allopurinol use, 2538 were associated with incident VA (8.8%). Among patients with incident VA, 54% were male, 78% were White, 75% had gout as the underlying diagnosis, and the mean Charlson–Romano comorbidity score was 4.8. The crude incidence of VA per 1,000,000 person-days declined as the duration of allopurinol use increased: 1–180 days, 151; 181 days to 2 years, 105; and > 2 years, 85. In multivariable-adjusted analyses, compared to non-use, allopurinol use was associated with lower HR of VA of 0.82 (95% CI, 0.76–0.90). Compared to allopurinol non-use, longer allopurinol use durations were significantly associated with lower multivariable-adjusted HR for VA: 1–180 days, 0.96 (95% CI, 0.85–1.08); 181 days to 2 years, 0.76 (95% CI, 0.68–0.85); and > 2 years, 0.72 (95% CI, 0.60–0.87). Multiple sensitivity analyses adjusting for cardiac conditions, anti-arrhythmic drugs and alternate definitions confirmed our findings with minimal/no attenuation of estimates. CONCLUSION: Allopurinol use and use duration of more than 6 months were independently associated with a lower risk of VA. Future studies need to assess the pathophysiology of this potential benefit. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-017-0816-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5361697
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53616972017-03-24 Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data Singh, Jasvinder A. Cleveland, John BMC Med Research Article BACKGROUND: There are no published human studies investigating whether the use of allopurinol, the most commonly used medication for the treatment of hyperuricemia in gout, the most common type of inflammatory arthritis in adults, has any beneficial effects on ventricular electrophysiology. The objective of our study was to assess whether allopurinol use is associated with a reduction in the risk of ventricular arrhythmias (VA). METHODS: We used the 5% random sample of Medicare beneficiaries from 2006–2012 to examine new allopurinol use and the risk of incident VA. Multivariable Cox regression analyses were adjusted for demographics (age, race, sex), comorbidity, cardiac medications, and conditions associated with VA. We calculated hazard ratios (HR) and 95% confidence intervals (CI). RESULTS: Of the 28,755 episodes of new allopurinol use, 2538 were associated with incident VA (8.8%). Among patients with incident VA, 54% were male, 78% were White, 75% had gout as the underlying diagnosis, and the mean Charlson–Romano comorbidity score was 4.8. The crude incidence of VA per 1,000,000 person-days declined as the duration of allopurinol use increased: 1–180 days, 151; 181 days to 2 years, 105; and > 2 years, 85. In multivariable-adjusted analyses, compared to non-use, allopurinol use was associated with lower HR of VA of 0.82 (95% CI, 0.76–0.90). Compared to allopurinol non-use, longer allopurinol use durations were significantly associated with lower multivariable-adjusted HR for VA: 1–180 days, 0.96 (95% CI, 0.85–1.08); 181 days to 2 years, 0.76 (95% CI, 0.68–0.85); and > 2 years, 0.72 (95% CI, 0.60–0.87). Multiple sensitivity analyses adjusting for cardiac conditions, anti-arrhythmic drugs and alternate definitions confirmed our findings with minimal/no attenuation of estimates. CONCLUSION: Allopurinol use and use duration of more than 6 months were independently associated with a lower risk of VA. Future studies need to assess the pathophysiology of this potential benefit. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-017-0816-6) contains supplementary material, which is available to authorized users. BioMed Central 2017-03-22 /pmc/articles/PMC5361697/ /pubmed/28327188 http://dx.doi.org/10.1186/s12916-017-0816-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Singh, Jasvinder A.
Cleveland, John
Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data
title Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data
title_full Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data
title_fullStr Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data
title_full_unstemmed Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data
title_short Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data
title_sort allopurinol and the risk of ventricular arrhythmias in the elderly: a study using us medicare data
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361697/
https://www.ncbi.nlm.nih.gov/pubmed/28327188
http://dx.doi.org/10.1186/s12916-017-0816-6
work_keys_str_mv AT singhjasvindera allopurinolandtheriskofventriculararrhythmiasintheelderlyastudyusingusmedicaredata
AT clevelandjohn allopurinolandtheriskofventriculararrhythmiasintheelderlyastudyusingusmedicaredata